Rosell, R., Karachaliou, N., Large-scale screening for somatic mutations in lung cancer. Lancet 387 (2016), 1354–1356.
Baraibar, I., et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit. Rev. Oncol. Hematol., 148, 2020, 102906.
Planchard, D., et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17 (2016), 984–993.
Drilon, A., et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 383 (2020), 813–824.
Gainor, J.F., et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). J. Clin. Oncol., 38, 2020, 9515.
Hong, D.S., et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 21 (2020), 531–540.
Doebele, R.C., et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21 (2020), 271–282.
Drilon, A., et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21 (2020), 261–270.
Wolf, J., et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N. Engl. J. Med. 383 (2020), 944–957.
Rotow, J., Bivona, T.G., Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer 17 (2017), 637–658.
Rikova, K., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
Liu, Y., et al. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib. Lung Cancer 129 (2019), 92–94.
Xu, S., et al. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib. BMC Cancer, 19, 2019, 769.
Lin, J.J., Shaw, A.T., Recent advances in targeting ROS1 in lung cancer. J. Thorac. Oncol. 12 (2017), 1611–1625.
Neel, D.S., et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Res. 79 (2019), 546–556.
Lin, J.J., et al. ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J. Thorac. Oncol. 12 (2017), 872–877.
Wang, R., et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J. Clin. Oncol. 30 (2012), 4352–4359.
Lindeman, N.I., et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. 13 (2018), 323–358.
Davies, K.D., et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J. Thorac. Oncol. 13 (2018), 1474–1482.
Chen, Y.F., et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations. J. Thorac. Oncol. 11 (2016), 1140–1152.
Robinson, D.R., et al. The protein tyrosine kinase family of the human genome. Oncogene 19 (2000), 5548–5557.
Shaw, A.T., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371 (2014), 1963–1971.
Moro-Sibilot, D., et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial. Ann. Oncol. 30 (2019), 1985–1991.
Mazieres, J., et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J. Clin. Oncol. 33 (2015), 992–999.
Wu, Y.L., et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36 (2018), 1405–1411.
Michels, S., et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J. Thorac. Oncol. 14 (2019), 1266–1276.
Drilon, A., et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7 (2017), 400–409.
Lim, S.M., et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J. Clin. Oncol. 35 (2017), 2613–2618.
Shaw, A.T., et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 20 (2019), 1691–1701.
Davare, M.A., et al. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E5381–E5390.
Davare, M.A., et al. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19519–19524.
Zou, H.Y., et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 3493–3498.
Chong, C.R., et al. Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer. Clin. Cancer Res. 23 (2017), 204–213.
Katayama, R., et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin. Cancer Res. 21 (2015), 166–174.
Katayama, R., et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat. Commun., 10, 2019, 3604.
Drilon, A., et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin. Cancer Res. 22 (2016), 2351–2358.
Sun, T.Y., et al. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J. Thorac. Oncol. 14 (2019), e21–e24.
Fujiwara, Y., et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget 9 (2018), 23729–23737.
Drilon, A., et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. Cancer Discov. 8 (2018), 1227–1236.
Ou, S., et al. OA09 preliminary clinical activity of repotrectinib (TPX-0005) in advanced ROS1 fusion-positive non-small cell lung cancer. J. Thorac. Oncol., 13, 2018, S1047.
Cho, B.C., et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J. Clin. Oncol., 37, 2019, 9011.
Harada, T., et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin. Cancer Res. 17 (2011), 2638–2645.
Vaishnavi, A., et al. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5 (2015), 25–34.
Cocco, E., et al. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15 (2018), 731–747.
Pulciani, S., et al. Oncogenes in solid human tumours. Nature 300 (1982), 539–542.
Barbacid, M., On the right TRK: from oncogene discovery to cancer therapeutics. Ann. Oncol. 30 (2019), viii3–viii4.
Rosen, E.Y., et al. TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin. Cancer Res. 26 (2020), 1624–1632.
Farago, A.F., et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis. Oncol., 2018, 2018, PO.18.00037.
Drilon, A., et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 7 (2017), 963–972.
Hyman, D., et al. Abstract CT127: phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res., 79, 2019, CT127.
Mulligan, L.M., RET revisited: expanding the oncogenic portfolio. Nat. Rev. Cancer 14 (2014), 173–186.
Ferrara, R., et al. Clinical and translational implications of RET rearrangements in non-small cell lung cancer. J. Thorac. Oncol. 13 (2018), 27–45.
Ju, Y.S., et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 22 (2012), 436–445.
Gautschi, O., et al. Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. J. Clin. Oncol. 35 (2017), 1403–1410.
Drilon, A., et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. Ann. Oncol. 27 (2016), 1286–1291.
Knowles, P.P., et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281 (2006), 33577–33587.
Drilon, A., et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat. Rev. Clin. Oncol., 15, 2018, 150.
Bronte, G., et al. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer (Auckl) 10 (2019), 27–36.
Subbiah, V., et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8 (2018), 836–849.
Solomon, B.J., et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15 (2020), 541–549.
Evans, E., et al. P2.03-44 BLU-667 demonstrates robust activity in RET fusion-driven intracranial tumor models. J. Thorac. Oncol., 14, 2019, S701.
Zhuo, M., et al. Analysis of MET kinase domain rearrangement in NSCLC. Lung Cancer 145 (2020), 140–143.
Reddy, V.P., et al. BRAF fusions in clinically advanced non-small cell lung cancer: an emerging target for anti-BRAF therapies. J. Clin. Oncol., 35, 2017, 9072.
Huang, Q., et al. Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma. Mol. Cancer Ther. 15 (2016), 2521–2529.
Plenker, D., et al. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci. Transl. Med., 9, 2017, eaah6144.
Campbell, J.D., et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat. Genet. 48 (2016), 607–616.
The Cancer Genome Atlas Research Network, Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
Tong, J.H., et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin. Cancer Res. 22 (2016), 3048–3056.
Liang, H., Wang, M., MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis. OncoTargets Ther. 13 (2020), 2491–2510.
Noonan, S.A., et al. Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis. J. Thorac. Oncol. 11 (2016), 1293–1304.
Cui, J.J., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J. Med. Chem. 54 (2011), 6342–6363.
Drilon, A., et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat. Med. 26 (2020), 47–51.
Paik, P.K., et al. Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N. Engl. J. Med. 383 (2020), 931–943.
Rotow, J.K., et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clin. Cancer Res. 26 (2020), 439–449.
Jamme, P., et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J. Thorac. Oncol. 15 (2020), 741–751.
Engstrom, L.D., et al. Glesatinib exhibits antitumor activity in lung cancer models and patients harboring MET exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models. Clin. Cancer Res. 23 (2017), 6661–6672.
Bahcall, M., et al. Acquired METD1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 6 (2016), 1334–1341.
Gatzemeier, U., et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 15 (2004), 19–27.
Clamon, G., et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 103 (2005), 1670–1675.
Shigematsu, H., et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65 (2005), 1642–1646.
Stephens, P., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431 (2004), 525–526.
Li, B.T., et al. HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J. Thorac. Oncol. 11 (2016), 414–419.
Pillai, R.N., et al. HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium. Cancer 123 (2017), 4099–4105.
Arcila, M.E., et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 18 (2012), 4910–4918.
Perera, S.A., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 474–479.
Shimamura, T., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66 (2006), 6487–6491.
Wang, S.E., et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10 (2006), 25–38.
Wang, Y., et al. Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers. BMC Cancer, 18, 2018, 326.
Mazieres, J., et al. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann. Oncol. 27 (2016), 281–286.
Mazieres, J., et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31 (2013), 1997–2003.
Robichaux, J.P., et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat. Med. 24 (2018), 638–646.
Chouitar, J., et al. P2.13-32 TAK-788 is a novel and potent tyrosine kinase inhibitor with selective activity against EGFR/HER2. J. Thorac. Oncol., 13, 2018, S811.
Neal, J., et al. P1.13-44 safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC. J. Thorac. Oncol., 13, 2018, S599.
Smit, E.F., et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. J. Clin. Oncol., 38, 2020, 9504.
Davies, H., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
Holderfield, M., et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 14 (2014), 455–467.
Leonetti, A., et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat. Rev. 66 (2018), 82–94.
Auliac, J.B., et al. Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14. Curr. Oncol. 25 (2018), e398–e402.
Litvak, A.M., et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J. Thorac. Oncol. 9 (2014), 1669–1674.
Tissot, C., et al. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Lung Cancer 91 (2016), 23–28.
Yao, Z., et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548 (2017), 234–238.
Nieto, P., et al. A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548 (2017), 239–243.
Gautschi, O., et al. Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF Cohort. J. Thorac. Oncol. 10 (2015), 1451–1457.
Mazieres, J., et al. Vemurafenib in non-small-cell lung cancer patients with BRAF(V600) and BRAF(nonV600) mutations. Ann. Oncol. 31 (2020), 289–294.
Subbiah, V., et al. Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis. Oncol., 3, 2019, PO.18.00266.
Planchard, D., et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol. 17 (2016), 642–650.
Planchard, D., et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 18 (2017), 1307–1316.
McLoughlin, E.M., et al. Clinical and radiographic response of leptomeningeal and brain metastases to encorafenib and binimetinib in a patient with BRAF V600E-mutated lung adenocarcinoma. J. Thorac. Oncol. 14 (2019), e269–e271.
Karoulia, Z., et al. New perspectives for targeting RAF kinase in human cancer. Nat. Rev. Cancer 17 (2017), 676–691.
Okimoto, R.A., et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 13456–13461.
Yao, Z., et al. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat. Med. 25 (2019), 284–291.
Sullivan, R.J., et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 8 (2018), 184–195.
Dudnik, E., et al. BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J. Thorac. Oncol. 13 (2018), 1128–1137.
Davies, K.D., et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One, 8, 2013, e82236.
Song, A., et al. Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer. Clin. Cancer Res. 21 (2015), 2379–2387.
Vaishnavi, A., et al. EGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinases. Cancer Res. 77 (2017), 3551–3563.
Dagogo-Jack, I., et al. Circulating tumor DNA identifies EGFR coamplification as a mechanism of resistance to crizotinib in a patient with advanced MET-amplified lung adenocarcinoma. J. Thorac. Oncol. 12 (2017), e155–e157.
McCoach, C.E., et al. Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer. Clin. Cancer Res. 24 (2018), 3334–3347.
Ding, G., et al. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. Cancer Biol. Ther. 20 (2019), 837–842.
Chang, H., et al. EGF induced RET inhibitor resistance in CCDC6-RET lung cancer cells. Yonsei Med. J. 58 (2017), 9–18.
Nelson-Taylor, S.K., et al. Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling. Mol. Cancer Ther. 16 (2017), 1623–1633.
Torigoe, H., et al. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer Sci. 109 (2018), 1493–1502.
Lin, J.J., et al. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann. Oncol. 31 (2020), 1725–1733.
Cocco, E., et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat. Med. 25 (2019), 1422–1427.
Wang, V.E., et al. Adaptive resistance to dual BRAF/MEK inhibition in BRAF-driven tumors through autocrine FGFR pathway activation. Clin. Cancer Res. 25 (2019), 7202–7217.
Riedel, R., et al. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Lung Cancer 133 (2019), 20–22.
Recondo, G., et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC. Clin. Cancer Res. 26 (2020), 2615–2625.
Rudin, C.M., et al. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J. Thorac. Oncol. 8 (2013), e41–e42.
Abravanel, D.L., et al. An acquired NRAS Q61K mutation in BRAF V600E-mutant lung adenocarcinoma resistant to dabrafenib plus trametinib. J. Thorac. Oncol. 13 (2018), e131–e133.
Niemantsverdriet, M., et al. KRAS mutation as a resistance mechanism to BRAF/MEK inhibition in NSCLC. J. Thorac. Oncol. 13 (2018), e249–e251.
Facchinetti, F., et al. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer. Eur. J. Cancer 132 (2020), 211–223.
Watanabe, J., et al. Appearance of a BRAF mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion. J. Thorac. Oncol. 13 (2018), e66–e69.
Dagogo-Jack, I., et al. Molecular analysis of plasma from patients with ROS1-positive NSCLC. J. Thorac. Oncol. 14 (2019), 816–824.
Ambrogio, C., et al. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene 36 (2017), 2309–2318.
Unni, A.M., et al. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife, 4, 2015, e06907.
Cisowski, J., et al. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF. Oncogene 35 (2016), 1328–1333.
Hong, A., et al. Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discov. 8 (2018), 74–93.
Sale, M.J., et al. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance. Nat. Commun., 10, 2019, 2030.
Xu, C.W., et al. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: a case report and literature review. Thoracic Cancer 8 (2017), 714–719.
Chuang, J.C., et al. ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies. J. Thorac. Oncol. 12 (2017), 833–842.
Dziadziuszko, R., et al. An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer. J. Thorac. Oncol. 11 (2016), 1273–1281.
Shen, A., et al. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res. 75 (2015), 4548–4559.
Somwar, R., et al. MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers. J. Clin. Oncol., 34, 2016, 9068.
Lin, L., et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat. Genet. 47 (2015), 250–256.
Sato, H., et al. MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions. Clin. Cancer Res. 26 (2020), 2932–2945.
Subbiah, V., et al. Phase I study of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in patients with BRAF-mutated malignancies. JCO Precis. Oncol., 2, 2018, PO.18.00189.
Subbiah, V., et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. J. Clin. Oncol., 36, 2018, 9035.
Subbiah, V., et al. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89 (2015), 76–79.
Sugano, T., et al. Inhibition of ABCB1 overcomes cancer stem cell-like properties and acquired resistance to MET inhibitors in non-small cell lung cancer. Mol. Cancer Ther. 14 (2015), 2433–2440.
Nahar, R., et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nat. Commun., 9, 2018, 216.
Maynard, A., et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182 (2020), 1232–1251.
Negrao, M.V., et al. Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. J. Thorac. Oncol. 15 (2020), 1611–1623.
Fernandes Neto, J.M., et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nat. Commun., 11, 2020, 3157.
Mazieres, J., et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann. Oncol. 30 (2019), 1321–1328.
Guisier, F., et al. Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018. J. Thorac. Oncol. 15 (2020), 628–636.
Corcoran, R.B., et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 8 (2018), 428–443.
Ortiz-Cuaran, S., et al. Circulating tumor DNA genomics reveal potential mechanisms of resistance to BRAF-targeted therapies in patients with BRAF-mutant metastatic non-small cell lung cancer. Clin. Cancer Res. 26 (2020), 6242–6253.
Maemondo, M., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362 (2010), 2380–2388.
Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11 (2010), 121–128.
Rosell, R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13 (2012), 239–246.
Sequist, L.V., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31 (2013), 3327–3334.
Zhou, C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12 (2011), 735–742.
Mok, T.S., et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376 (2017), 629–640.
Soria, J.C., et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378 (2018), 113–125.
Niederst, M.J., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21 (2015), 3924–3933.
Thress, K.S., et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
Piotrowska, Z., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5 (2015), 713–722.
Choi, Y.L., et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68 (2008), 4971–4976.
Kwak, E.L., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363 (2010), 1693–1703.
Shaw, A.T., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370 (2014), 1189–1197.
Soria, J.C., et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389 (2017), 917–929.
Shaw, A.T., et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 17 (2016), 234–242.
Camidge, D.R., et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 379 (2018), 2027–2039.
Solomon, B.J., et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19 (2018), 1654–1667.
Pratilas, C.A., et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68 (2008), 9375–9383.
Noeparast, A., et al. Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib. Oncotarget 8 (2017), 60094–60108.
Kim, S.Y., et al. Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma. Sci. Rep., 9, 2019, 19909.
Joshi, M., et al. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One, 10, 2015, e0118210.
Noeparast, A., et al. Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Oncotarget 9 (2018), 16110–16123.
Nichols, R.J., et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20 (2018), 1064–1073.
Bracht, J.W.P., et al. BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: the need for a new pre-clinical treatment rationale. Cancers, 11, 2019, 1381.
Cope, N.J., et al. Analyses of the oncogenic BRAF(D594G) variant reveal a kinase-independent function of BRAF in activating MAPK signaling. J. Biol. Chem. 295 (2020), 2407–2420.
Yoh, K., et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. Lancet Respir. Med. 5 (2017), 42–50.
Lee, S.H., et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann. Oncol. 28 (2017), 292–297.
Drilon, A., et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 17 (2016), 1653–1660.
Hida, T., et al. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Lung Cancer 138 (2019), 124–130.
Drilon, A., et al. A phase I/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105. Cancer Discov. 9 (2019), 384–395.
Peters, S., et al. Activity of afatinib in heavily pretreated patients with ERBB2 mutation-positive advanced NSCLC: findings from a global named patient use program. J. Thorac. Oncol. 13 (2018), 1897–1905.
Lai, W.V., et al. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. Eur. J. Cancer 109 (2019), 28–35.
Dziadziuszko, R., et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J. Thorac. Oncol. 14 (2019), 1086–1094.
Kris, M.G., et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann. Oncol. 26 (2015), 1421–1427.
Hyman, D.M., et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554 (2018), 189–194.
Wang, Y., et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann. Oncol. 30 (2019), 447–455.
Robichaux, J.P., et al. Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 36 (2019), 444–457.
Awad, M.M., et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368 (2013), 2395–2401.
Gainor, J.F., et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. JCO Precis. Oncol., 2017, 2017, PO.17.00063.
Facchinetti, F., et al. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers. Clin. Cancer Res. 22 (2016), 5983–5991.
Dagogo-Jack, I., et al. Emergence of a RET V804M gatekeeper mutation during treatment with vandetanib in RET-rearranged NSCLC. J. Thorac. Oncol. 13 (2018), e226–e227.
Nakaoku, T., et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat. Commun., 9, 2018, 625.
Drilon, A., et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378 (2018), 731–739.
Koga, T., et al. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study. Lung Cancer 126 (2018), 72–79.
Kosaka, T., et al. Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res. 77 (2017), 2712–2721.
Heist, R.S., et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 11 (2016), 1242–1245.
Ou, S.I., et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 12 (2017), 137–140.
Schrock, A.B., et al. Mutation of MET Y1230 as an acquired mechanism of crizotinib resistance in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 12 (2017), e89–e90.
